Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Mohan, M.; Cruz, J. C.; Nath, R.; Anwer, F.; Rossi, A.; Htut, M.; Malik, S. A.; Ghatta, S.; Dillon, M.; Ying, W.; Navale, L.; Karski, E. E.; Balakumaran, A.; Kumar, S. K. |
| Abstract Title: | Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 4620 |
| End Page: | 4622 |
| Language: | English |
| ACCESSION: | WOS:000893223204284 |
| DOI: | 10.1182/blood-2022-158231 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
